4-aminopyrrolopyrimidines as kinase inhibitors

Details 4-aminopyrrolopyrimidines as kinase inhibitors 4-aminopyrrolopyrimidines as kinase inhibitors

2011-01-04

2011-01-04

Rao, Deepak (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C514S265100

Reexamination Certificate

active

07863444

ABSTRACT:
Chemical compounds having structural formula Iand physiologically acceptable salts thereof, are inhibitors of serine/threonine and tyrosine kinase activity. Several of the kinases whose activity is inhibited by these compounds are involved in immunologic, hyperproliferative or angiogenic processes. Thus, these compounds can ameliorate disase states where angiogenesis or endothelial cell hyperproliferaton is a factor. These compounds can be used to treat cancer, hyperproliferative disorders, rheumatoid artheritis, disorders of the immune system, transplant rejection, and inflammatory disorders.

REFERENCES:
patent: 4140851 (1979-02-01), Townsend
patent: 4229453 (1980-10-01), Roth et al.
patent: 4892865 (1990-01-01), Townsend et al.
patent: 4927830 (1990-05-01), Townsend et al.
patent: 4968686 (1990-11-01), Townsend et al.
patent: 4996206 (1991-02-01), Taylor et al.
patent: 5028608 (1991-07-01), Taylor et al.
patent: 5248775 (1993-09-01), Taylor et al.
patent: 5254687 (1993-10-01), Taylor et al.
patent: 5344932 (1994-09-01), Taylor
patent: 5349064 (1994-09-01), Akimoto et al.
patent: 5416211 (1995-05-01), Barnett et al.
patent: 5593997 (1997-01-01), Dow et al.
patent: 5594121 (1997-01-01), Froehler et al.
patent: 5612482 (1997-03-01), Barnett et al.
patent: 5639757 (1997-06-01), Dow et al.
patent: 5644057 (1997-07-01), Yuan et al.
patent: 5644058 (1997-07-01), Barnett et al.
patent: 5665721 (1997-09-01), Bhagwat et al.
patent: 5686457 (1997-11-01), Traxler et al.
patent: 5721356 (1998-02-01), Ugarkar et al.
patent: 5726302 (1998-03-01), Ugarkar et al.
patent: 5763596 (1998-06-01), Boyer et al.
patent: 5763597 (1998-06-01), Ugarkar et al.
patent: 5834469 (1998-11-01), Elliott et al.
patent: 6001839 (1999-12-01), Calderwood et al.
patent: 6660744 (2003-12-01), Hirst et al.
patent: 6713474 (2004-03-01), Hirst et al.
patent: 30 36 390 (1982-05-01), None
patent: 0 402 903 (1990-12-01), None
patent: 0 496 617 (1992-07-01), None
patent: 0 795 556 (1997-09-01), None
patent: WO 94 17803 (1994-08-01), None
patent: WO 96/10028 (1996-04-01), None
patent: WO 96/40686 (1996-12-01), None
patent: WO 96/40705 (1996-12-01), None
patent: WO 96/40706 (1996-12-01), None
patent: WO 96/40707 (1996-12-01), None
patent: WO 97/02266 (1997-01-01), None
patent: WO 97/03069 (1997-01-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO 97/28161 (1997-08-01), None
patent: WO 97/32879 (1997-09-01), None
patent: WO 97/34895 (1997-09-01), None
patent: WO 98 41525 (1998-09-01), None
Hanke, J.H., et al., “Discovery of a Novel, Potent, and Src Family—selective Tyrosine Kinase Inhibitor; Study of Lck- and FynT-dependent T Cell Activation,”J Biol Chem., 271(2):695-701, 1996.
Traxler, P.M., et al., “4-(Phenylamino)pyrrolopyrimidines: Potent and Selective, ATP Site Directed Inhibitors of the EGF-Receptor Protein Tyrosine Kinase,”J. Med. Chem., 39:2285-2292 (1996).
Showalter, H.D.H., et al., “Synthesis and SAR for a series of 4-substituted 1H-pyrimido[4,5-b] and 5H-pyrimido[5,4-b]indoles as EGF receptor tyrosine kinase inhibitors,” Proceedings of the American Association for Cancer Research, vol. 37, Mar. 1996 (abstract).
Missbach, M., et al., “A Novel Inhibitor of the Tyrosine Kinase Src Suppresses Phosphorylation of Its Major Cellular Substrates and Reduces Bone Resorption In Vitro and in Rodent Models In Vivo,”Bone, 24(5) :437-449 (1999).
Dave, C.G., et al., “Synthesis & Biological Activity of Pyrrolo[2,3-d]pyrimidines,”Indian J. Chem., 27B:778-780 (1988).

Affiliated with

Also associated with

Rating

4-aminopyrrolopyrimidines as kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 4-aminopyrrolopyrimidines as kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 4-aminopyrrolopyrimidines as kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2699905